|
|
|
|
|
|
|
|
|
|
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial
"For currently unknown reasons, administering PLD with carboplatin appears to substantially reduce the incidence of platinum-associated hypersensitivity reactions."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.